KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Alnylam Pharmaceuticals (ALNY) EBIAT (2016 - 2025)

Historic EBIAT for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $111.5 million.

  • Alnylam Pharmaceuticals' EBIAT rose 23316.5% to $111.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $278.1 million, marking a year-over-year increase of 19997.91%. This contributed to the annual value of $313.7 million for FY2025, which is 21279.49% up from last year.
  • Alnylam Pharmaceuticals' EBIAT amounted to $111.5 million in Q4 2025, which was up 23316.5% from $251.1 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBIAT registered a high of $251.1 million during Q3 2025, and its lowest value of -$405.9 million during Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' EBIAT averaged around -$121.2 million, with its median value being -$156.0 million (2023).
  • Examining YoY changes over the last 5 years, Alnylam Pharmaceuticals' EBIAT showed a top increase of 32504.62% in 2025 and a maximum decrease of 29242.7% in 2025.
  • Alnylam Pharmaceuticals' EBIAT (Quarter) stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then surged by 233.17% to $111.5 million in 2025.
  • Its last three reported values are $111.5 million in Q4 2025, $251.1 million for Q3 2025, and -$66.3 million during Q2 2025.